Cell Reports, Volume 42

## Supplemental information

## A PINK1 input threshold arises from positive

## feedback in the PINK1/Parkin mitophagy

## decision circuit

Christopher S. Waters, Sigurd B. Angenent, Steven J. Altschuler, and Lani F. Wu



**Figure S1. Identification of an internal Parkin tagging site that preserves function, related to Figure 1. (A)** Parkin domain map. UBL: ubiquitin-like. ACT: activating. REP: repressive. Four RING-like domains: RING0, RING1, IBR (in between RING), and RING2. Selected residues marked. M1 indicates Parkin's N-terminal methionine. **(B)** Immunofluorescence (IF) approach for assessing Parkin function. HeLa cells lack endogenous Parkin expression. Parkin expressed by transient transfection (methods). Anti-TOM20 stains mitochondria. Bar length not to scale. **(C)** Parkin fusion proteins, assessed for activity. M1L mutation was carried over from the mCherry-Parkin cloning source and was corrected to make Nterm-M1(corr.). LD: ligase dead **(D)** Conservation of residues at Parkin's internal tagging site. **(E)** Change in Parkin localization due to CCCP treatment (methods). Co-localization (Co-loc.), intensity correlation (Pearson; methods). Mean, 95% confidence intervals, and statistical significance calculated by bootstrap analysis (B=10,000). Bonferroni multiple comparison adjustment. \*\*\*p<0.001; n.s.: not significant. **(F)** Representative images showing Parkin recruitment. Scale bars: 20um. **(G)** Mean TOM20 depletion due to CCCP treatment. Bootstrap approach as in (E). AFU, arbitrary fluorescence units. **(H)** Representative images showing TOM20 loss. Scale bars: 20um. **(I-K)** Human Parkin structure (PDB: 5C1Z). **(I)** Full protein. **(J)** UBL domain. **(K)** N-terminus (N.t.) of UBL domain. Carbon: color gradient. Oxygen: red. Nitrogen: blue. Sulfur, yellow. Dotted lines: predicted interactions. #: predicted salt bridge between E16 and the N.t.  $NH_3^+$  which would be disrupted by any N-terminal tag. **(L-N)** N.t. structures of human Ubiquitin and other N.t. UBL domains (PDB: 1F9J, 1UEL, and 1NDD respectively). **(O)** N.t. structure of human HOIL1's internal UBL domain (PDB: 2LGY). N.t. of ubiquitin fold stabilized by additional interactions involving D54. Gray coloring: N-terminal extension to canonical UBL fold. **(P)** Sequence logo showing amino acid conservation in UBL domains. Analysis across unique UBL domains in the Uniprot database (methods). Residues used for motif-based alignment are marked (methods). **(Q)** E16A Parkin mutant phenocopies functional defect of N-terminal tags. Functional evaluation as in  $(E-G)$ .



**Figure S2. Characterization of the PINK1/Parkin synthetic circuit, related to Figure 1 and 2. (A)** MtTether localization matches that of mitochondrial protein TOM20. Top: Representative images. Bottom: pixel intensities along white lines in images. Scale bar: 20um. **(B)** Average PINK1<sup>mito</sup> levels are relatively stable over time. Mean and standard deviation, per imaging timepoint, across 1987 normalized cell traces (methods). **(C)** Relationship between PINK1<sup>mito</sup> and cellular expression of PINK1 and MtTether. Points: 1987 individual cells, colored by MtTether expression level. Lines: empirical trends **(D)** Representative live-cell imaging of mitochondrial loss following prolonged rapalog-driven PINK1<sup>mito</sup> and Parkin<sup>mito</sup> recruitment. Asterisk: cell of interest. Dotted line: cell boundary. Scale bars: 10um. **(E)** Kinase dead (KD) PINK1 (G386A) is not capable of recruiting Parkin. Points: single-cell measurements of fixed cells, colored by local point density. **(F)** Effect of rapalog treatment on mTOR signaling (pS6; methods). Rapamycin: positive control, 100nM. Rapalog: 200nM. (G-H) Parkin<sup>mito</sup> recruitment correlated with pUbmito levels. **(G)** Representative images of two cells: with or without antipUbmito staining and Parkinmito fluorescence. Scale bars: 10um. **(H)** Fixed cell analysis and comparison of anti-pUb staining. Left: linear correlation between amounts of pUb<sup>mito</sup> and Parkin<sup>mito</sup>. Right: Parkin<sup>mito</sup> intensity correlation detects Parkin<sup>mito</sup> recruitment before pUb<sup>mito</sup> levels detectably rise. Points: single-cell measurements of fixed cells, colored by local point density. **(I-J)** Re-analysis of circuit input and response from Fig. 2A for alternative response metric: max fraction of Parkin on mitochondria. Vertical line, re-calculated PINK1 input threshold (methods). Points, 1987 individual cells, colored by local point density. Y-axis shown with linear (I) and log (J) scales for clearer visualization. **(K-L)** Measurement of the PINK1/Parkin synthetic circuit behavior using fixed cell analysis. **(K)** Experimental approach. Bar length not to scale. **(L)** Single-cell Parkin<sup>mito</sup> localization versus PINK1<sup>mito</sup> concentration at various rapalog treatment durations. Points: single-cell measurements of fixed cells, colored by local point density, pooled from three experimental replicates. Vertical lines, PINK<sup>mito</sup> concentration for cells undergoing Parkin<sup>mito</sup> recruitment (methods). Progressive datapoint scarcity caused by mitochondrial degradation.



**Figure S3. Effect of Parkin expression on PINK1/Parkin synthetic circuit dynamics, related to Figure 2. (A-D)** The effect of Parkin expression levels on synthetic circuit behavior. **(A)** Distribution of single-cell Parkin expression levels, from the synthetic circuit's standard EF1a promoter, split into three equally sized groups (percentage of total noted). Live-cell data from four experiments was pooled. Counts normalized to bin width (density). **(B)** Quantification of PINK1 input threshold (top) and reciprocal activation delay hyperbola (bottom) for cells in expression groups in (A). Points: individual cells, colored by local point density. **(C)** Threshold and hyperbolas from (B), overlaid. **(D)** Bootstrap statistical analysis of input threshold and delay scaler values for data in (B-C). Mean, 95% confidence intervals, and statistical significance calculated by bootstrap analysis (B=10,000). Bonferroni multiple comparison adjustment. \*\*p<0.01; n.s.: not significant. **(E-H)** Circuit behaviors preserved at ultralow Parkin expression levels. **(E)** Ultralow Parkin expression driven by a truncated CMV promoter, CMV(trunc.), compared to that of the EF1a promoter, measured by fluorescence microscopy. Values for EF1a promoter differ from (A) due to longer exposure times required to image CMV(trunc.) condition. **(F)** Quantification of circuit behaviors for expression conditions in (E) from live cells. Increased noise in the CMV(trunc.) from Parkin expression approaching instrument's background fluorescence levels. **(G)** Threshold and hyperbolas from (F), overlaid. **(H)** Bootstrap statistical analysis of input threshold and delay scaler values for data in (F-G). Mean, 95% confidence intervals, and statistical significance calculated by bootstrap analysis (B=10,000). Bonferroni multiple comparison adjustment. \*\*\*p<0.001. **(I)** Characterization of Parkin expression levels compared to that of endogenous Parkin in human brain lysate. Amount of loaded protein is listed for each lane. Filled/empty triangles indicate endogenous/mKO2-tagged Parkin respectively. Band intensity quantification shown for lane 2 and 3 normalized to GAPDH and compared to lane 4 (methods). Fold difference of expression between EF1a and CMV(trunc.) differs from (E) due to effect of background fluorescence in CMV(trunc.) condition. Double band in lane 3 may indicate presence of truncated protein. Decreased protein function due to truncation may contribute to increased threshold and delay in (F-H) causing overestimation of the repressive effect of ultralow Parkin expression.

















**Figure S4. Single-cell data for evaluating behavior of PINK1 and Parkin mutants, related to Figure 3 and 4. (A)** PINK1 (green) and Parkin (red) mutation effects in full circuit context. Mutation arrows/T-bars: enhancement/repression (resp.). All affects are modulatory, except for S65A which completely blocks Parkin phosphorylation by PINK1. Relative strength of W403A bypass is unknown. **(B)** Single-cell source data for Fig. 3C-D. Points: single-cell measurements of fixed cells, colored by local point density. Single-cell data pooled from two plate replicates. Vertical black lines: estimated PINK1<sup>mito</sup> concentration of cells undergoing Parkin<sup>mito</sup> recruitment (methods). Progressive datapoint scarcity caused by mitochondrial degradation. Bottom row: rescaled x-axis for clearer visualization. **(C)** Single-cell source data for Fig. 4C. Representation and analysis as in (B). Single-cell data pooled from two experimental replicates of three plate replicates each. **(D)** Effect of Parkin mutations on PINK1 circuit behavior. Points: aggregate quantification from fixed cell measurements in  $(C)$ . n.d.: not determined due to lack of Parkin<sup>mito</sup> recruitment. **(E-F)** Single-cell source data for Fig. 4D. Representation and analysis as in (C-D). Single-cell data pooled from two experimental replicates of three plate replicates each.





**Figure S5. Input-coupled positive feedback produces threshold and reciprocal activation delay behavior, related to Figure 5. (A)** Rate equations for minimal model of input-coupled positive feedback circuit as in Fig. 5A. Parameters *E*\* and *C*\* govern input threshold and reciprocal activation delay, respectively. **(B)** Rate analyses for example values of *E* below or above the input threshold. Forward  $(k_{fb} * E * X * pX)$  and reverse  $(k_{rev} * pX)$  reaction rates are plotted (methods). Stable steady states (SSS) and unstable steady states (USS) are identified. **(C)** Steady state analysis illustrating the system's transcritical bifurcation (TCB) that defines the input threshold (methods). For input, *E,* levels below the TCB, the system has one stable steady. For input, *E,* values above the TCB, the system has two stable states, one stable and one unstable (B, right). **(D)** Exponential growth of *pX* from  $pX_{init}$  to  $pX_{det}$  for various values of *E* (methods). Equation describing hyperbolic relationship between *E* and time to reach  $pX_{det}$  is shown. **(E)** Relationship between *E* and time to reach  $pX_{det}$  (methods). Examples from (F), marked with empty circles. **(F)** Parameterized more complete model of the PINK1/Parkin circuit. Variables are defined: Parkin, *A*; Ubiquitin, *U*; PINK1, *E*. Numbered rate constants "*k <sup>i</sup>*" are indexed by step. **(G)** Simple schematic of the model. Rate of each step obtained by multiplying the source moiety (e.g.  $U_f$ ) by the rate shown (e.g.  $k_1$ ).



**Figure S6. Additional characterization of the PINK1/Parkin synthetic circuit, related to** Figure 1 and 2. (A) Endogenous PINK1<sup>mito</sup> levels are much lower than that of the synthetic circuit. Comparison of endogenous PINK1<sup>mito</sup> levels following CCCP treatment versus ectopically expressed PINK1<sup>mito</sup> levels following rapalog treatment for single cells (methods). The measured PINK1 input threshold is noted for reference. Schematic: experimental approach. FPs: fluorescent proteins. Imaging channels noted. Schematic bar lengths not to scale. **(B)** Chemical structure of the USP30 inhibitor, CMPD39. **(C)** Quantification of circuit behaviors from live-cell data. CMPD39 or vehicle treatment begun 2 hours prior to rapalog treatment (methods). Points: individual cells, colored by local point density. Data from four experimental replicates was pooled. **(D)** Threshold and hyperbolas from (C), overlaid. **(E)** Bootstrap statistical analysis of input threshold and delay scaler values for data in (C). Mean, 95% confidence intervals, and statistical significance calculated by bootstrap analysis (B=10,000). Bonferroni multiple comparison adjustment. \*p<0.05; \*\*\*p<0.001.